SCHOTT Pharma Q4 2025 Earnings Call — Results and Strategic Outlook
SCHOTT Pharma's Q4 2025 call outlined steady top-line growth, margin gains and investments in sterile glass vials. Management gave a cautious FY26 outlook while prioritizing capacity expansion.
Seeking Alpha
2 min read
Stocks
Market Analysis
Healthcare